Coagulation Market is expected to reach US$ 10,853.28 million by 2030

Publisher: The Insight Partners

Liver Disease Segment Held Largest Share in Coagulation Market Based on Disease Indications in 2022

According to our new research study on “Coagulation Market Forecast to 2030 – Global Analysis – by Disease Indications, Type, Offering, Technology, and End User,” the coagulation market is expected to grow from US$ 6,295.28 million in 2022 to US$ 10,853.28 million by 2030; it is anticipated to record a CAGR of 7.0% from 2022 to 2030. The report emphasizes the trends prevalent in the global coagulation market, along with drivers and deterrents affecting its growth. 

Based on disease indications, the coagulation market is segmented into vitamin K deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von Willebrand disease, and others. The liver disease segment held the largest market share in 2022. However, the hemophilia segment is anticipated to register the highest CAGR during 2022–2030. Chronic liver diseases affect people of all genders, ages, regions, and races worldwide. Cirrhosis is the result of several liver diseases, and it is characterized by fibrosis and architectural distortion of the liver, and the formation of regenerative nodules. These diseases are known to have a broad range of clinical manifestations and complications. The prevalence of liver disease has steadily increased over the years. According to national statistics, liver diseases rank fifth among the leading causes of death in the UK. These diseases are also the second leading cause of death in the US among all digestive diseases. According to the World Gastroenterology Organization, the global prevalence of cirrhosis ranges from 4.5% to 9.5% of the general population.

Coagulation Market, by Region, 2022 (%)

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00030085

Source: The Insight Partners Analysis

NORDIC BIOMARKER; ImproGen Diagnostik Kimya San. & Tic. Ltd; Diagnostica Stago, Inc; Siemens Healthcare Private Limited; Sysmex, Helena Biosciences; F. Hoffmann-La Roche Ltd; Genrui Biotech Co; Ltd; Transasia Bio-Medicals; and HORIBA Medical are a few of the key companies operating in the coagulation market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name.

The report segments the coagulation market as follows: 

Based on disease indications, the coagulation market is segmented into vitamin K deficiency, liver disease, disseminated intravascular coagulation & pulmonary embolism, development of circulating anticoagulants, hemophilia, von Willebrand disease, and others. The liver disease segment held the largest share of the coagulation market in 2022. Further, the hemophilia segment is anticipated to register the highest CAGR from 2022 to 2030.

Based on type, the coagulation market is bifurcated into clinical laboratory analyzers and point-of-care testing analyzers. Clinical laboratory analyzers are further categorized as controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others. The clinical laboratory analyzers segment held a larger share of the coagulation market in 2022. Further, the point-of-care testing analyzers segment is anticipated to register a higher CAGR from 2022 to 2030.

Based on offering, the coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger share of the market in 2022. Further, the treatment segment is anticipated to register a higher CAGR in the coagulation market during 2022–2030.

Based on technology, the coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest share of the market in 2022. It is anticipated to register the highest CAGR in the coagulation market during 2022–2030.

The coagulation market, by end user, is segregated into clinical laboratories, hospitals, and others. The clinical laboratories segment held the largest share of the market in 2022, and it is anticipated to register the highest CAGR in the coagulation market during 2022–2030.

Based on geography, the coagulation market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com